Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIPT with Verteporfin for Cutaneous Breast Cancer Metastases
NCT02939274Phase 2Unknown
- Sponsor
- Rogers Sciences
- Start
- Oct 2016
- Primary completion
- Dec 2018
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of verteporfin in breast cancer, sponsored by Rogers Sciences. Primary endpoint: Objective Response Rate at Day 23. Status: unknown.
02
Drugs
verteporfin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02939274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939274.